Medicine
Marplan 10 mg tablet
Marplan 10 mg tablet is a prescription medicine containing Isocarboxazid for oral use, marketed by Lifsa Drugs, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 77ºF (25ºC), excursions permitted to 59º to 86ºF (15º to 30ºC).
Key facts
- Active ingredient (INN)
- Isocarboxazid
- Brand
- Marplan
- Strength
- 10 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Lifsa Drugs
- Manufacturer
- Lifsa Drugs
- Origin register
- US FDA, United States
- Storage
- Store at 77ºF (25ºC), excursions permitted to 59º to 86ºF (15º to 30ºC).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06AF01 Isocarboxazid
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 July 1959
- Identifiers
- RxCUI 104837, 201708DailyMed set ID 95fde749-44ad-4668-86c4-0ff17bca0074NDC 72336-032Application NDA011961
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle, plastic | 72336-032-01 | Lifsa Drugs | 1 July 1959 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 1 July 1959 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Isocarboxazid is a monoamine oxidase inhibitor indicated for the treatment of depression. It is available as tablets for oral use. MedsAcross supplies Isocarboxazid for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IsocarboxazidFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- MARPLAN prescribing information (Lifsa Drugs) · U.S. National Library of Medicine, DailyMed
Need Marplan 10 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.